<SEC-DOCUMENT>0001193125-21-029893.txt : 20210205
<SEC-HEADER>0001193125-21-029893.hdr.sgml : 20210205
<ACCEPTANCE-DATETIME>20210205081128
ACCESSION NUMBER:		0001193125-21-029893
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20210205
FILED AS OF DATE:		20210205
DATE AS OF CHANGE:		20210205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		21593782

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d37821d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;5, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.2&#151;Press Release
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d37821dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g37821imab.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Announces Multiple Clinical Advancements of its
Differentiated CD73 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Antibody Uliledlimab in China and the U.S. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- </B><B><I>First patient dosed in a combination study with <FONT STYLE="white-space:nowrap">anti-PD1</FONT> in China</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- </B><B><I>Topline results from U.S. phase 1 study demonstrate safety and clinical activity</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- </B><B><I>Data from preclinical and clinical studies to be presented at conferences this year</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China and GAITHERSBURG, MD. </B>&#150; February&nbsp;5, 2021<B> </B>&#150; <FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB), a
clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprietary and highly differentiated CD73
antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors. The Company plans to present detailed clinical results at select scientific conferences this year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CD73 is implicated in tumor resistance to checkpoint immunotherapies as it plays a critical role in adenosine-mediated immune suppression in tumor
microenvironment. Uliledlimab is a humanized CD73 antibody and works effectively on modulating tumor microenvironment through inhibition of the adenosine pathway. Uliledlimab is shown to strongly suppress tumor growth especially when combined with a
<FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitor in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. As a differentiated CD73 antibody, uliledlimab interacts with a unique epitope to function through a novel intra-dimer binding
mode, thus enabling differentiated and favorable functional properties. Detailed data from the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and mechanistic studies have been submitted for presentation at the upcoming American Association of
Cancer Research Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> has made significant progress in the global clinical development of
uliledlimab. In China, <FONT STYLE="white-space:nowrap">I-Mab</FONT> is advancing the phase 1/2 dose escalation and cohort expansion study of uliledlimab as a single agent and in combination with toripalimab (TUOYI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced or metastatic cancers who are refractory to or intolerant of available therapies. On February&nbsp;3, 2021, the first patient in the combination study was dosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the U.S., <FONT STYLE="white-space:nowrap">I-Mab</FONT> has completed the initial assessment of its clinical study investigating uliledlimab monotherapy <FONT
STYLE="white-space:nowrap">lead-in</FONT> followed by combination with atezolizumab (Tecentriq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with solid tumors. Topline results from a clinical study under contract with TRACON
show that uliledlimab is safe and well tolerated at the dose range evaluated and demonstrate clinical activity in patients with advanced solid tumors. The Company is scheduled to submit an abstract to ASCO for the 2021 annual meeting. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g37821imab.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged and very pleased by the clinical results and overall advancements of uliledlimab in
both China and the U.S.,&#148; said Dr.&nbsp;Joan Shen, CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;We believe that the combination of uliledlimab with immune checkpoint inhibitors, such as toripalimab or atezolizumab, has the
potential to offer a novel treatment option with intended clinical benefit in cancer patients who do not or poorly respond to current checkpoint immunotherapies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Uliledlimab (TJD5) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular
adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing
tumor growth in concert with checkpoint therapies such as <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer
binding, leading to differentiated and favorable functional properties as evident in preclinical studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq:&nbsp;IMAB) is an innovation-driven global biotech
company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company&#146;s mission is to bring transformational medicines to patients around the world
through drug innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 15 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by its internal R&amp;D
capability and global licensing partnerships, based on the Company&#146;s unique
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global
R&amp;D capabilities, a world-class GMP manufacturing facility and commercialization capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in&nbsp;Shanghai (headquarters),&nbsp;Beijing,&nbsp;Hangzhou
and&nbsp;Hong Kong in China,&nbsp;and&nbsp;Maryland and San Diego in the United States. For more information, please visit <U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow
<FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g37821imab.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding data from the TJD5 phase 1 trial, the potential implications of clinical data for patients, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> advancement of, and anticipated clinical development,
regulatory milestones and commercialization of TJD5. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and
timing of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial
success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
reliance on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain
additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial
and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well
as discussions of potential risks, uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on
information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gigi Feng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Communications Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+86 21 6057 8000</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d37821dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g37821log.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Announces First Patient Dosed in Phase 2 Clinical Trial of
TJ107 in Glioblastoma Multiforme in China </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China and GAITHERSBURG, MD.,</B> <B>February </B><B>4</B><B>, </B><B>2021 &#150;</B> <FONT
STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has
been dosed in a phase 2 clinical trial (<U>NCT04600817</U>) of TJ107<FONT STYLE="font-family:pmingliu"> </FONT><FONT STYLE="font-family:Times New Roman">(efineptakin alpha), a novel long-acting recombinant human
<FONT STYLE="white-space:nowrap">interleukin-7</FONT> <FONT STYLE="white-space:nowrap">(rhIL-7),</FONT> in patients with glioblastoma multiforme (GBM) in China. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phase 2 trial is a randomized, single-blind, placebo-controlled study to evaluate the efficacy and safety of TJ107 in lymphopenic patients with newly
diagnosed GBM who have been treated with standard concurrent chemoradiotherapy. The study&#146;s goal is to determine the proportion of patients with an increase in the absolute lymphocyte counts and associated clinical response after the
administration of the first TJ107 dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is increasing evidence that lymphopenia induced by radiotherapy and chemotherapy is associated with poor
survival in cancer patients. In case of GBM, standard treatments induce long-lasting lymphopenia in most patients, and currently there are no definitive therapies for it. A phase 1b study conducted by Genexine Inc. (KOSDAQ: 095700) demonstrated that
TJ107 rapidly increased absolute lymphocyte counts and restored T cell counts especially in the na&iuml;ve and memory subsets but not the regulatory T cells in terminally ill patients with solid tumors. TJ107 was well tolerated with no dose-limiting
toxicity or cytokine release syndrome observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Despite advances in standard therapy, GBM is associated with poor clinical outcomes and survival
rates,&#148; said Professor Wenbin Li, Director of Department of Neuro-Oncology at Beijing Tiantan Hospital of Capital Medical University and the leading principal investigator of the clinical trial. &#147;Based on its preclinical and clinical data,
TJ107 promises to improve tolerance to the standard therapy, quality of life and prognosis in patients with GBM, and we look forward to making this drug accessible to our patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;TJ107 is the first and only long-acting <FONT STYLE="white-space:nowrap">rhIL-7</FONT> in the clinical stage globally and early studies have shown its
potential to treat patients with GBM whose prognosis is still poor,&#148; said Dr.&nbsp;Joan Shen, Chief Executive Officer of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;The initiation of the phase 2 trial brings us one step closer to
delivering a highly innovative therapy to treat patients with one of the most life-threatening forms of cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM is the most aggressive type of
glial cancer which can arise in the brain <I>de novo</I> or evolve from existing tumors. GBM accounts for 17% of new brain and nervous system cancers in China, according to data from the World Health Organization in 2018.<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ostrom Q T, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous
system tumors diagnosed in the United States in 2010&#150;2014[J]. Neuro-oncology, 2017, 19(suppl_5): <FONT STYLE="white-space:nowrap">v1-v88.</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g37821log.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TJ107/GX-I7</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TJ107/GX-I7&nbsp;(efineptakin</FONT> alpha) is the world&#146;s first and only long-acting recombinant human <FONT
STYLE="white-space:nowrap">interleukin-7</FONT> <FONT STYLE="white-space:nowrap">(rhIL-7),</FONT> known to boost T lymphocytes by increasing their number and functions.&nbsp;It emerged&nbsp;from&nbsp;Genexine&#146;s proprietary hyFc<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform for discovering of long-acting biologics. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has acquired exclusive rights from Genexine to develop and commercialize <FONT
STYLE="white-space:nowrap">TJ107/GX-I7&nbsp;in</FONT> Greater&nbsp;China. <FONT STYLE="white-space:nowrap">TJ107/GX-I7</FONT> may have utility in cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in
cancer patients who have received chemotherapy or radiation therapy, for which there is no approved treatment. TJ107/ <FONT STYLE="white-space:nowrap">GX-I7</FONT> has&nbsp;also&nbsp;been shown to synergize with a
<FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in various tumor animal models potentially through increased <FONT STYLE="white-space:nowrap">T-lymphocyte</FONT> activation and proliferation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq:&nbsp;IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic
area. The Company&#146;s mission is to bring transformational medicines to patients around the world through drug innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 15 clinical and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by its internal R&amp;D capability and global licensing partnerships, based on the Company&#146;s unique
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global
R&amp;D capabilities, a world-class GMP manufacturing facility and commercialization capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in&nbsp;Shanghai (headquarters),&nbsp;Beijing,&nbsp;Hangzhou
and&nbsp;Hong Kong in China,&nbsp;and&nbsp;Maryland and San Diego in the United States. For more information, please visit <U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow
<FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT>
Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and other federal securities laws, including statements regarding data from the <FONT STYLE="white-space:nowrap">TJ107/GX-I7</FONT> phase 1/2 trial, the potential implications of clinical data for patients, and
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> advancement of, and anticipated clinical development, regulatory milestones and commercialization of TJ107/ <FONT STYLE="white-space:nowrap">GX-I7.</FONT> Actual results may differ materially from
those indicated in the forward-looking statements as a result of various important factors, including but not limited to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the
clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial success for its drug candidates, if approved;
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance on third parties to conduct drug
development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional funding for operations and to
complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other operations, as well as those
risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks,
uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as may be required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g37821log.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu <BR>Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng <BR>Chief Communications Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">The Piacente Group, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g37821imab.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g37821imab.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MS;3M^DX/'8;&T_:8:IS))-JUI)/573Z/HU==F=S7T!UA0 4 % !0 4 % !0
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M+_T[4/U%^!7_ "1'X.?]DK^'O_J):17PF:_\C3,O^PK$?^GIGW^4?\BG+/\
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M$G!?A$]3K[,] _&;_@I'_P E8\#_ /9.X/\ U)?$%?I?!/\ R+\5_P!A#_\
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MX1\/1>$_#&A>&X91.NC:;;637 C\D7,T: W%SY6]_*\VX,LFS<VW?C<<9/\
M=F197#(\GRW*:<_:QP%"G1<^7D]I**]^IRWER\\W*?+S2M>UWN?>X:BL-AZ-
M!/F5**C>UKM;NVMKN[L='7JFY\S?%GXFWWA;X@Z9X9D^(^D?#K1[CP:==6[U
M#P=-XJFU'4O[;FT]K:,0W4)M(X[5%?)!!->YE^!A7P<Z_P!2GC*D:WL[1K*D
MHQY%*^J=VWH>#F./GAL;3P_UZ&!I.C[1.5%U7*7.XVT:Y4DKD6C_ !;UZ_\
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K3<7/E]T]DKY8^W"@ H * "@ H * "@ H * "@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g37821log.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g37821log.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M\,?M^_!RY_9E_;U^)/AF>%H+4ZU-J.G_ "X5K2Y;[1!M/?"2!3C^)6':M_\
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-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
